Matches in Nanopublications for { ?s ?p "[Therefore, interrupting the RAS-MAPK pathway by an ERK1/2 inhibitor (apigenin) or an AURKB inhibitor (barasertib) might be a new strategy for overcoming cetuximab resistance in HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 3 of
3
with 100 items per page.
- assertion description "[Therefore, interrupting the RAS-MAPK pathway by an ERK1/2 inhibitor (apigenin) or an AURKB inhibitor (barasertib) might be a new strategy for overcoming cetuximab resistance in HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_assertion description "[Therefore, interrupting the RAS-MAPK pathway by an ERK1/2 inhibitor (apigenin) or an AURKB inhibitor (barasertib) might be a new strategy for overcoming cetuximab resistance in HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217326.RADG7PviTvwt-ECkAo4oJJEw_ri_NDqh83_Yk2GxJERBg130_provenance.
- NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_assertion description "[Therefore, interrupting the RAS-MAPK pathway by an ERK1/2 inhibitor (apigenin) or an AURKB inhibitor (barasertib) might be a new strategy for overcoming cetuximab resistance in HNSCC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217325.RArSRcJUpmJwsYHt--q0lrFjw1fZ6gwYXXPGkxVhNcK6c130_provenance.